First Trust Advisors’s Vir Biotechnology VIR Stock Holding History

First Trust Advisors’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-12,656	Closed	-$92.9K	–	2632
2024 Q4	$92.9K	Buy	+12,656	New	+$99.8K	﹤0.01%	2529
2023 Q3	–	Sell	-132,962	Closed	-$3.26M	–	2497
2023 Q2	$3.26M	Sell	132,962 -108,588	-45%	-$2.73M	﹤0.01%	1454
2023 Q1	$5.62M	Sell	241,550 -20,902	-8%	-$535K	0.01%	1174
2022 Q4	$6.64M	Buy	262,452 +115,459	+79%	+$2.83M	0.01%	1087
2022 Q3	$2.83M	Buy	146,993 +125,819	+594%	+$3.2M	﹤0.01%	1501
2022 Q2	$539K	Sell	21,174 -61,536	-74%	-$1.44M	﹤0.01%	2180
2022 Q1	$2.13M	Buy	82,710 +65,152	+371%	+$1.93M	﹤0.01%	1757
2021 Q4	$735K	Sell	17,558 -32,814	-65%	-$1.29M	﹤0.01%	2171
2021 Q3	$2.19M	Sell	50,372 -45,395	-47%	-$1.97M	﹤0.01%	1738
2021 Q2	$4.53M	Buy	+95,767	New	+$4.35M	﹤0.01%	1435

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

First Trust Advisors's VIR Position: Q1 2025 in Review

First Trust Advisors sold out of Vir Biotechnology (VIR) in Q1 2025, closing a stake of 12,656 shares — an estimated $92.9K sold.

First Trust Advisors first reported a position in VIR in Q2 2021 and held it in 10 quarters. The position peaked at $6.64M in Q4 2022. 233 funds tracked by Wall St. Rank hold VIR as of Q1 2025.

First Trust Advisors reported no remaining Vir Biotechnology position as of Q1 2025 after selling out during the quarter.
First Trust Advisors sold 12,656 Vir Biotechnology shares in Q1 2025, an estimated $92.9K.
First Trust Advisors first reported a position in Vir Biotechnology in Q2 2021 and held it in 10 quarters.
First Trust Advisors's Vir Biotechnology position peaked at $6.64M in Q4 2022.
233 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2025.

Based on First Trust Advisors's 13F filing for Q1 2025, filed 14 May 2025.